New drug for lymphoma that has returned or not responded
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, BMS-986458, alone or with other lymphoma treatments, for people with non-Hodgkin lymphoma that has come back or not gotten better after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old with non-Hodgkin lymphoma that has come back or not responded to treatment.
- Your lymphoma must be measurable on scans, with at least one spot larger than 1.5 cm.
- If you can become pregnant or father a child, you must agree to use effective birth control.
- You must be able to follow the study rules and avoid certain other treatments.
- You cannot have had certain prior treatments (like CAR-T or radiation) within the last few weeks or months, depending on the specific treatment group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, LY4584180, for adults with several types of non-Hodgkin lymphoma who have already had at least two prior treatments. The goal is to see if the drug can help shrink tumors and stop the cancer from growing.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This study tests an experimental drug (GSK5926371) for people with a type of lymphoma (B-cell NHL) that has come back or not responded to earlier treatments. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
Hear when a new Relapsed/Refractory Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.